Renal Impairment: Clinical Trials

15 trials for Renal Impairment, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 4 unknown, 2 terminated, 1 withdrawn. 15 Phase 2, 4 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 215Completed 8, Unknown 4, Terminated 2, Withdrawn 1
Phase 14Completed 3, Terminated 1
Phase 31Unknown 1

Follow Renal Impairment: new trials by email Literature Review of Renal Impairment trials Research Report on Renal Impairment

Trials (filtered) newest first · largest first

All 15 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor
Isatuximab, Pomalidomide, Dexamethasone - Multiple Myeloma, Renal Impairment
Phase 2UnknownHellenic Society of Hematology1082022-05-012022-03-28
A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment
Isatuximab, Bortezomib, Cyclophosphamide - Multiple Myeloma, Renal Impairment
Phase 2UnknownHellenic Society of Hematology512022-04-012022-03-29
Neuromuscular Blockade in Patients With Severe Renal Impairment
Cisatracurium + Neostigmine, Rocuronium + Sugammadex - Neuromuscular Blockade, Renal Impairment
Phase 2CompletedUniversity of Texas Southwestern Medical Center492019-12-102023-11-08
PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Function
Melflufen, Dexamethasone - Renal Impairment, Multiple Myeloma
Phase 2TerminatedOncopeptides AB352018-08-282023-03-10
Study of PK/PD, Safety and Tolerability of LIK066 in Patients With Decreased Renal Function.
LIK066 - Renal Impairment
Phase 2CompletedNovartis Pharmaceuticals532017-04-282021-01-05
An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis.
Simeprevir (SMV) 150 mg, Daclatasvir (DCV) 60 mg - Renal Impairment, End-stage Renal Disease
Phase 2WithdrawnJanssen R&D Ireland2015-05-012015-07-17
Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Diastolic Cardiomyopathy (Aim3)
Tadalafil, Placebo - Cardiomyopathy, Renal Impairment
Phase 1 / Phase 2CompletedMayo Clinic222014-03-012020-10-28
Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systolic Cardiomyopathy (Aim2)
Tadalafil, Placebo - Cardiomyopathy, Renal Impairment
Phase 1 / Phase 2CompletedMayo Clinic202014-01-092021-06-11
CNI-free "Bottom"-up Immunosuppression in Patients Undergoing Liver Transplantation
delayed, low-dose CNI, BU-CNI, BU-Everolimus - Renal Impairment, Liver Transplantation
Phase 2 / Phase 3UnknownUniversity of Regensburg452011-06-012011-07-01
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
Febuxostat, Placebo - Renal Impairment
Phase 2CompletedTakeda962010-04-012013-09-25
Bicarbonate and Lipocalin in Systemic Inflammatory Response Syndrome (SIRS) Study
Sodium bicarbonate, Sodium chloride - Systemic Inflammatory Response Syndrome, Oliguria
Phase 2CompletedAustin Health702010-02-012014-06-30
Pharmacokinetics of Vildagliptin in Mild, Moderate and Severe Renal Impaired Patients
Vildagliptin - Renal Impairment, Diabetes
Phase 1 / Phase 2CompletedNovartis Pharmaceuticals962008-12-012020-12-17
Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy Females
50 mg Proellex - Renal Impairment
Phase 1 / Phase 2TerminatedRepros Therapeutics Inc.62008-10-012014-08-25
Low-dose Albumin Solution in SBP: a Randomized Double-blind Pilot Study
Albumin - Renal Impairment, All Cause Mortality
Phase 2UnknownHospital de Clinicas de Porto Alegre432006-03-012010-06-07
Effects of MK7418 on Diuresis and Renal Function in Congestive Heart Failure Patients
rolofyline, Comparator Placebo (unspecified) - Congestive Heart Failure, Renal Impairment
Phase 2CompletedNovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)1602004-12-012008-04-04

Narrower conditions

Renal Insufficiency (15)  ·  Multiple Myeloma (3)  ·  Blood Protein Disorders (2)  ·  Cardiomyopathies (2)  ·  Hematologic Diseases (2)  ·  Neoplasms (2)  ·  Neoplasms by Histologic Type (2)  ·  Neoplasms, Plasma Cell (2)  ·  Paraproteinemias (2)  ·  Diabetes Mellitus (1)  ·  Gout (1)  ·  Heart Failure (1)  ·  Hyperuricemia (1)  ·  Kidney Diseases (1)  ·  Kidney Failure, Chronic (1)

Broader conditions

Female Urogenital Diseases (15)  ·  Female Urogenital Diseases and Pregnancy Complications (15)  ·  Male Urogenital Diseases (15)  ·  Urogenital Diseases (15)  ·  Urologic Diseases (15)  ·  Kidney Diseases (14)  ·  Cardiovascular Diseases (6)  ·  Heart Diseases (3)  ·  Hemic and Lymphatic Diseases (3)  ·  Hemorrhagic Disorders (3)  ·  Hemostatic Disorders (3)  ·  Immune System Diseases (3)  ·  Immunoproliferative Disorders (3)  ·  Lymphoproliferative Disorders (3)  ·  Pathologic Processes (3)

Interventions

Dexamethasone (3)  ·  Tadalafil (2)  ·  isatuximab (2)  ·  Acetaminophen (1)  ·  Albumins (1)  ·  Bortezomib (1)  ·  Cyclophosphamide (1)  ·  Diphenhydramine (1)  ·  Febuxostat (1)  ·  L-melphalanyl-p-L-fluorophenylalanine ethyl ester (1)  ·  Lenalidomide (1)  ·  Neostigmine (1)  ·  Ranitidine (1)  ·  Rocuronium (1)  ·  Saline Solution (1)

Sponsors

Hellenic Society of Hematology (2)  ·  Mayo Clinic (2)  ·  Novartis Pharmaceuticals (2)  ·  Austin Health (1)  ·  Hospital de Clinicas de Porto Alegre (1)  ·  Janssen R&D Ireland (1)  ·  NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1)  ·  Oncopeptides AB (1)  ·  Repros Therapeutics Inc. (1)  ·  Takeda (1)  ·  University of Regensburg (1)  ·  University of Texas Southwestern Medical Center (1)

Countries

United States (6)  ·  Greece (3)  ·  Australia (1)  ·  Brazil (1)  ·  Czechia (1)  ·  France (1)  ·  Germany (1)  ·  Poland (1)  ·  Russia (1)  ·  Spain (1)

Top investigators

Evangelos Terpos, Prof (2)  ·  Horng H Chen, MD (2)  ·  Alexandre Araujo (1)  ·  Andre van As, MD, PhD (1)  ·  Andreas A Schnitzbauer, MD (1)  ·  Gabriela Rossi (1)  ·  Hans J Schlitt, MD (1)  ·  Michael C Reade, MBBS DPhil (1)  ·  Nerina Harley, MBBS FCICM (1)

Results publications

PMID 26894653, PMID 35001638, PMID 37295665

NIH funding

2008 (1), 2014 (1), 2016 (1), 2018 (1)